Jiangsu Qyun Bio-Pharma

Jiangsu Qyun Bio-Pharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of antibody-based therapies for autoimmune and allergic diseases. Headquartered in Taizhou, China, the company utilizes its proprietary Q-Platform to manage the full drug development lifecycle, from initial discovery to large-scale GMP manufacturing. Its lead product candidate, QX001N, is a biosimilar to ustekinumab developed in partnership with Walvax Biotechnology and is currently under NDA review in China for the treatment of plaque psoriasis. The company's robust pipeline also includes innovative monoclonal antibodies targeting IL-17A, IL-4Rα, and IL-23, addressing significant unmet needs in dermatology, rheumatology, and respiratory medicine. Qyun Bio successfully listed on the Hong Kong Stock Exchange in 2024, further accelerating its clinical programs and manufacturing expansion.